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Blood  and  plasma  donations  in  Germany  are  collected  by  several
institutions,  namely  the  German  Red  Cross,  community  and
hospital-based  blood  services,  private  blood  centres,  commercial
plasma donation sites and transfusion services of the army. All blood
donation  centres  are  required  to  report  quarterly  data  on  infection
markers  to  the  Robert  Koch  Institute,  thus  providing  current  and
accurate epidemiological data. The prevalence and incidence of relevant
viral infections are low in the blood donor population in Germany, with a
decreasing trend for hepatitis C infections in new and repeat donors
since 1997. The implementation of mandatory nucleic acid amplification
technique  (NAT)  testing  for  hepatitis  C  virus  (HCV)  in  1999  has
markedly improved transfusion safety. HIV-NAT became mandatory in
2004 but was done voluntarily by the majority of the blood donation
services before then. The potential benefit of hepatitis B virus (HBV)
minipool NAT is not as clear because chronic HBV carriers with very low
virus levels might donate unidentified. The residual risk of an infectious
window period donation inadvertently entering the blood supply can be
estimated using a mathematic model which multiplies the incidence rate
by the number of days during which an infection may be present but not
detectable,  i.e.  the  length  of  the  window  period.  The  risk  of  an
undetected infection without NAT testing was estimated to be 1 in 2
770 000 for HIV, 1 in 670 000 for HCV and 1 in 230 000 for HBV in
2001/2002. This contrasts with 1 in 5 540 000 for HIV, 1 in 4 400 000
for  HCV and  1  in  620  000  for  HBV with  minipool  NAT testing.  This
demonstrates  that  NAT  testing  can  further  reduce  the  already  very
small risk of infectious donations entering the blood supply.
 
Introduction
Protection of the blood supply from virus-infected donations has reached a very
high level due to effective donor selection and testing with the latest techniques.
The most sensitive diagnostic method suitable for donor screening, nucleic acid
amplification technique (NAT) testing, has become mandatory for hepatitis C
virus (HCV) and human immunodeficiency virus (HIV)-1 in Germany in 1999 and
2004, respectively. Surveillance of infectious disease markers in the blood donor
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population is important in recognising trends in prevalence and incidence of
transfusion related infections. It also provides an opportunity to estimate the risk
of an infectious donation inadvertently entering the blood supply. Mathematic
models applied to surveillance data help evaluate the potential benefit of new
tests, like the introduction of minipool or individual donation NAT. Epidemiological
data on HIV, HCV and hepatitis B virus (HBV) infections has been systematically
analysed in Germany since 1996 and reporting of detected infections has become
mandatory with the enactment of the Transfusion Act in July 1999. The Robert
Koch-Institute (RKI) collects and analyses nationwide data. In Germany, more
than 100 individual blood donation services collect several thousand to several
hundred thousand donations per year. In this report we present data collected
from 2000 to 2002, including residual risk estimates which are representative for
all German blood donations.
Methods
Data were obtained from the RKI nationwide blood donation infection surveillance
and included more than 99% of all donations in 2000 and 100% of all donations
in 2001 and 2002. Blood and plasma donation centres reported aggregated data
on number and type of donations from new and repeat donors and the number of
confirmed HIV, HCV and HBV infections. Detailed serological results from all
positive donors were available. An infection was considered confirmed positive if
a reactive screening result was verified by an appropriate supplementary test in a
different test system and/or NAT. During the study period all blood donations
were screened for anti-HIV 1/2, anti-HCV, HCV genome and hepatitis B surface
antigen (HbsAg). A large number of donations was also screened with HIV-1 NAT,
HBV NAT and to a lesser extent, tested for anti-HBc on a voluntary basis. A
minimum sensitivity of 5000 IU/ml with respect to the individual donation was
required for HCV-NAT testing. Sensitivity of NAT had to be validated with limiting
dilutions followed by probit analysis as recommended by the German licensing
agency, the Paul-Ehrlich-Institute [1]. The majority of donations were screened
with an in-house Taqman PCR in minipools of up to 96 samples [2,3]. To a lesser
extent, donations were tested using commercially available NAT tests or in-house
NAT with small pool sizes or with individual donation-NAT. All NAT-only positive
results had to be confirmed either by later seroconversion or by positive NAT
from a second independently drawn blood sample.
Prevalence was calculated as number of infections in all individuals who
presented at the blood donation centre for the first time (new donors).
Seroconversions refer to all confirmed infections found in donations from repeat
donors. Infection rates were compared to data from previous nationwide studies
on infectious disease markers in blood donors [4,5,6]. Trends were calculated
using a Chi Square test for linear trends, 95% confidence intervals (CI) were
determined using a binomial distribution. Additional data on NAT-only positives
from the NAT-study of the German Red Cross (GRC) blood donor service were
included (Roth, written communication). Residual risk calculations were
performed using a modified incidence rate/window period model [7,8]: Briefly,
the residual risk attributable to window period donations was calculated as
(window period) x (adjusted incidence/person years at risk).
Window periods for testing procedures were derived from the literature [7,9].
Incidence was calculated as number of seroconversions for HIV, HCV and HBV
reported to the RKI in the study period, respectively (“crude incidence”).
Donations which would not have entered the blood supply due to an additional
positive test result (ALT, syphilis) or a confidential self exclusion were subtracted
from the number of seroconversions to calculate the ”adjusted incidence” used in
the model. For HBsAg, risk was calculated both with and without the correction
factor to compensate for the transient nature of HBsAg [10]. The correction
factor was determined to be 2.73 calculated from the individual interdonation
intervals of the HBV-positive donations from German blood donors. Person years
at risk were derived from the number of repeat whole blood donations from
donors who had given at least 2 donations within the 2 year study periods
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(“regular donors”) between 2000/2001 and 2001/2002 divided by the mean
interdonation interval length (0.52 years).The window period for HBsAg was
reduced by 9 days to account for the higher sensitivity of HBsAg tests used in
Germany compared with FDA licensed tests commonly used for the
determination of the window period [11]. Residual risks were calculated for the 2
overlapping periods 2000/2001 and 2001/2002.
Results
German blood donation services tested 17 925 610 donations during the 3 year
study period from 2000 to 2002. Of these, 91.2% were donations from repeat
donors. The proportion of whole blood donations was 77.9%. Test results from
new donors and repeat donors respectively are given in Table 1 including data
from previous studies [5,6].
Comparing the results of blood donor screening in Germany from 1997 to 2002
the prevalence of HBV infections remains relatively stable whereas HIV
prevalence increased in 2002. Seroconversion rates for both infections did not
change significantly over time. HCV infections, however, demonstrate a
significant decrease since 1997, both for prevalence (from 148.8 to 97.4
infections/105 new donors, p<0.000) and for the rate of seroconversions (from
2.6 to 1.5 infections/105 donations from repeat donors, p<0.000).
From 2000 to 2002, more than 17 million donations were reported to the RKI
representing > 99 % of all collected donations including those of the GRC. All
donations were tested with HCV NAT. With HIV-1 and HBV NAT not being
mandatory in the study period, the proportion of donations screened for HIV-1
and HBV genome could not be determined exactly but certainly exceeded 60%.
The GRC blood donor service collects about 75 % of all whole blood donations in
Germany and implemented NAT testing as early as 1996 in some centres for all
three viruses [12]. The NAT study of the GRC included more than 21 million
donations from January 1997 to October 2003. The number of NAT-only positive
donations for both studies is given in Table 2.
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The residual risk of an infectious window period donation entering the blood
supply unrecognised was calculated using the epidemiological data reported to
the RKI. Data are shown for two overlapping two-year periods 2000/2001 and
2001/2002. With the same test systems in place the estimated window periods
remained the same in both observation periods. The decrease of the adjusted
incidence of HCV and to a lesser extend also of HIV lead to a reduction of the
estimated residual risk of window period donations. In 2001/2002 it was
calculated to be 1 in 2 770 000 for HIV, 1 in 670 000 for HCV and 1 in 230 000
for HBV (corrected) without NAT and 1 in 5 540 000 for HIV, 1 in 4 400 000 for
HCV and 1 in 620 000 for HBV with minipool NAT. The risk of an undetected
window period donation could be further reduced to 1 in 820,000 for HBV with ID
NAT. The results are shown in Table 3:
Discussion
Infection rates among blood donors in Germany are low and since 1997, a
significant decrease with regard to HCV infections among new and repeat donors
has been observed. Similar trends were also found in other countries [13,14].
The recent rise in HIV prevalence has to be investigated carefully to reveal
possible changes in donor characteristics. People seeking free-of-charge HIV
tests results by donating blood might contribute to the observed rise in
prevalence. Case control studies are necessary to verify this hypothesis.
The implementation of HCV NAT has lead to the identification of 11 otherwise
unrecognised HCV-positive donations as reported to the RKI between 2000 and
2002. The benefit of the introduction of HCV NAT was also reflected in the
national haemovigilance report [15]. No HCV transmissions have been reported
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to the Paul-Ehrlich-Institute since HCV NAT testing became mandatory. The
additional gain in safety achieved by introduction of HIV-1 NAT is not quite as
marked due to the smaller reduction in the diagnostic window period compared
with HCV NAT. Still, HIV-1 NAT did identify some otherwise undetected infectious
donations which might have led to transmissions – an important result with
respect to the severity of the disease. HBV NAT proved helpful in reducing HBV
transmissions but this depends largely on the sensitivity of the NAT performed.
With the highly sensitive PCR minipool testing following virus enrichment as
performed by the GRC [2], 47 HBV NAT-only positive donations could be
identified including preseroconversion donors as well as chronic HBsAg-negative
HBV carriers. Still, some infectious are missed by minipool NAT after enrichment
or even by individual donation NAT [1]. Compared to sensitive HBsAg tests
standard minipool NAT can only add little to reduce the window period for HBV
infections [16]. Due to the slow replication rate of HBV in the early phase of
infection, only a very sensitive individual donation HBV NAT (e.g. with a detection
limit of 50 copies/ml or less) would help to avoid a greater number of undetected
infectious donations [17]. Another approach to reduce HBV-transmissions is to
introduce additional anti-HBc testing to identify chronic HBV carriers with a very
low viral load. There is evidence that blood components containing anti-HBc and
anti-HBs do not transmit HBV [18]. Therefore re-entry of donors with anti-HBc
and anti-HBs (>100 IU/l) who are negative in individual donation HBV NAT
should be taken into consideration to minimise the prospective loss of donors if
anti-HBc screening were introduced in Germany. Finally both measures,
individual donation-NAT and anti-HBc testing should be carefully evaluated in
terms of cost-benefit [19,20]. The observed difference between the RKI’s
reported numbers and GRC data with respect to HBV NAT-only donations can be
explained by the fact that the reporting of an (initially non confirmed) NAT-only
positive result is not yet mandatory in Germany. Obviously, these infections are
mainly reported after follow up testing revealed seroconversion or presence of
HBsAg.
The residual risk of infectious window period donations entering the blood supply
in Germany is low. The implementation of HCV NAT and the significant decrease
in HCV incidence among repeat donors has lead to a measurable fall in the
estimated residual risk. Also the implementation of HIV-1 and HBV NAT has an
impact on the risk of undetected infectious donations because of the shortening
of the window period. Comparing risk estimates between countries remains
difficult as the mathematical models used are commonly adapted to the specific
national data characteristics leading to significant differences in risk estimates
[21].
Residual risk estimates always have limitations. The determining factor in the
equation is the length of the window period which may vary considerably
depending on the specificity and sensitivity of the test used. This might also hold
true for the German data with different NAT tests and different pool sizes or
individual donation-NAT in place. The used window period derived from the
literature reflect average sensitivity of minipool NAT which is higher in some
blood donation services especially when individual donation NAT is performed
and consequently leads to a smaller residual risk. Furthermore, in our model we
considered all window period donations to be infectious although during the early
ramp-up phase of viral replication, this might not be the case [22]. It must also
be kept in mind that given risk estimates are derived from repeat whole blood
donors only and might therefore underestimate the true number of undetected
infectious donations, as it has been shown that new donors might pose a greater
risk of infectious donations than repeat donors [23]. Also, other influencing
factors such as test or process errors or mutant viruses that are not detected by
blood donor screening are not considered in the model. Still, keeping those
limitations in mind, the residual risk model was able to demonstrate the benefit of
NAT techniques in reducing window period donations especially for HCV and HIV.
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